Skip to main content

Virtual Patients Refine Search for Safe & Effective Immuno-oncology Combo Therapies

By Vijayalakshmi Chelliah, Georgia Lazarou, Piet van der Graaf and Andrzej Kierzek Immuno-oncology (IO) represents an elegant solution; it uses a patient’s own immune system to fight their cancer. Early IO research used monoclonal antibodies to induce an immune response from patients’ PD1/PD-L1 and CTLA4 receptors, which serve as immune system checkpoints, successfully achieving long-term … Continued

Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm

Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit through reprograming of cellular responses. In immuno‐oncology (IO) the aim is to direct the patient’s own immune system to fight cancer. After remarkable successes of antibodies targeting PD1/PD‐L1 and CTLA4 receptors in targeted patient populations, the focus of further development … Continued

Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology

Bispecific antibodies (bsAbs) have become an integral component of the therapeutic research strategy to treat cancer. In addition to clinically validated immune cell re‐targeting, bsAbs are being designed for tumor targeting and as dual immune modulators. Explorative preclinical and emerging clinical data indicate potential for enhanced efficacy and reduced systemic toxicity. However, bsAbs are a … Continued

Simcyp: 20 Years of Innovation

The consortium members have partnered with Simcyp and Certara during the past 20 years to advance the science of drug development through modeling & simulation

1 of 6